Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Parallel, Active-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in Peripheral Neuropathic Pain

NCT03221907 is registered in ClinicalTrials.gov with Daewon Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03221907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03221907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Parallel, Active-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in Peripheral Neuropathic Pain
Lead sponsor
Daewon Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 11, 2016
Completion date
January 8, 2019
Enrollment
352 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pain of mononeuropathy